供卵受体不能从胚胎植入前非整倍体检测中获益
该配对队列研究分析了2012至2018年美国47家IVF中心的1291个供卵受体周期,比较同一供者卵子用于接受PGT-A(262周期)与未接受PGT-A(1029周期)的受体夫妇的结局。结果显示PGT-A组活产率53.8%,未PGT-A组55.8%(P=0.44),差异无统计学意义;PGT-A避免了12.7%无整倍体胚胎周期的移植,但未改善活产。
要点
- 供卵受体中PGT-A未提高活产率(53.8% vs 55.8%,P=0.44)。
- PGT-A避免了12.7%无整倍体胚胎周期的移植。
- PGT-A组平均移植胚胎数1.09枚,低于未PGT-A组的1.38枚(P<0.01)。
核心结论
- 对玻璃化供卵受体,PGT-A未改善活产可能性,但避免了无整倍体胚胎周期的移植。
研究设计与样本
- 配对队列研究,分析2012至2018年美国47家IVF中心的供卵受体周期。
- 共纳入223名供者的1291个起始受体周期,其中262周期行PGT-A,1029周期未行PGT-A。
- 采用广义估计方程模型控制混杂因素,并以供者自身为对照嵌套分析。
主要发现
- 每个受体周期的中位非整倍体率为25%。
- PGT-A组平均移植1.09枚胚胎,未PGT-A组平均移植1.38枚(P<0.01)。
- PGT-A组活产率53.8%,未PGT-A组55.8%(P=0.44)。
- 按受体周期计算的累积活产率结果相似。
临床怎么用
- 供卵受体周期中不应常规使用PGT-A以期提高活产率。
- PGT-A可避免无整倍体胚胎周期的移植,但增加费用和时间。
- 研究结果是否适用于使用自体卵子的年轻不孕人群尚需进一步研究。
局限性
- 汇总47家IVF诊所的临床数据,PGT-A在胚胎实验室、检测公司和平台上存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do donor oocyte recipients benefit from preimplantation genetic testing for aneuploidy (PGT-A)? SUMMARY ANSWER: PGT-A did not improve the likelihood of live birth for recipients of vitrified donor oocytes, but it did avoid embryo transfer in cycles with no euploid embryos. WHAT IS KNOWN ALREADY: Relative to slow freeze, oocyte vitrification has led to increased live birth from cryopreserved oocytes and has led to widespread use of this technology in donor egg IVF programs. However, oocyte cryopreservation has the potential to disrupt the meiotic spindle leading to abnormal segregation of chromosome during meiosis II and ultimately increased aneuploidy in resultant embryos. Therefore, PGT-A might have benefits in vitrified donor egg cycles. In contrast, embryos derived from young donor oocytes are expected to be predominantly euploid, and trophectoderm biopsy may have a negative effect relative to transfer without biopsy. STUDY DESIGN, SIZE, DURATION: This is a paired cohort study analyzing donor oocyte-recipient cycles with or without PGT-A performed from 2012 to 2018 at 47 US IVF centers. PARTICIPANTS/MATERIALS, SETTING, METHODS: Vitrified donor oocyte cycles were analyzed for live birth as the main outcome measure. Outcomes from donors whose oocytes were used by at least two separate recipient couples, one couple using PGT-A (study group) and one using embryos without PGT-A (control group), were compared. Generalized estimating equation models controlled for confounders and nested for individual donors contributing to both PGT-A and non-PGT-A cohorts, enabling a single donor to serve as her own control. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 1291 initiated recipient cycles from 223 donors were analyzed, including 262 cycles with and 1029 without PGT-A. The median aneuploidy rate per recipient was 25%. Forty-three percent of PGT-A cycles had only euploid embryos, whereas only 12.7% of cycles had no euploid embryos. On average 1.09 embryos were transferred in the PGT-A group compared to 1.38 in the group without PGT-A (P < 0.01). Live birth occurred in 53.8% of cycles with PGT-A versus 55.8% without PGT-A (P = 0.44). Similar findings persisted in cumulative live birth from per recipient cycle. LIMITATIONS, REASONS FOR CAUTION: Pooled clinical data from 47 IVF clinics introduced PGT-A heterogeneity as genetic testing were performed using different embryology laboratories, PGT-A companies and testing platforms. WIDER IMPLICATIONS OF THE FINDINGS: PGT-A testing in donor oocyte-recipient cycles does not improve the chance for live birth nor decrease the risk for miscarriage in the first transfer cycle but does increase cost and time for the patient. Further studies are required to test if our findings can be applied to the young infertility patient population using autologous oocytes. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Doyle N, Gainty M, Eubanks A, et al. Donor oocyte recipients do not benefit from preimplantation genetic testing for aneuploidy to improve pregnancy outcomes. Hum Reprod. 2020. PMID: 33057600. doi:10.1093/humrep/deaa219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。